about
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.Tau PET imaging: present and future directions.Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's diseaseImaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's diseaseComparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding.Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ speciesLongitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's diseaseOptimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [F]THK5317 PETSpatial Normalization of 18F-Flutemetamol PET Images Using an Adaptive Principal-Component TemplateTau PET imaging in neurodegenerative tauopathies-still a challenge
P50
Q30235197-4E0BEECC-023C-4998-A622-CF70D430DC60Q34680852-FBF62F36-3DEF-47CF-9D77-C60A25BDB855Q35905536-EC647CEF-0921-40C1-9CD4-7148FE7FF9A8Q36615510-77620B28-807E-4869-AC83-22DF80FB9D55Q37063163-AF8CB3A2-0003-4966-8E53-60067FAF8980Q37294936-EB515FF4-6E8C-495D-AA12-2F3056D59C6AQ39970942-092E52CE-BD4B-4C70-B71E-CF966606497FQ40077992-ED944A66-72C7-4A09-860D-B81F02AC2871Q48345360-BF14C544-C0C8-4269-A42C-EC61F5507DF9Q48799327-F9F0F6E1-5188-4C92-B957-43CF2DCC675EQ55416644-DFFD1836-6B72-442B-A09B-A2AFB8014CDCQ58766037-86AA7FD4-B37F-4529-A2E8-86C0B309293AQ61452191-17EA7555-BF05-4CB3-929F-CAC811011F34Q61811940-F186CF6F-D4C5-4A85-BF82-F4011C0B2B81Q89108147-90B5517C-1B2C-4EBE-8431-B6B1A5EE6A2AQ91011085-54BB080C-25AC-4726-AF52-CE02E8AB7C98
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Konstantinos Chiotis
@ast
Konstantinos Chiotis
@en
Konstantinos Chiotis
@es
Konstantinos Chiotis
@nl
Konstantinos Chiotis
@sl
type
label
Konstantinos Chiotis
@ast
Konstantinos Chiotis
@en
Konstantinos Chiotis
@es
Konstantinos Chiotis
@nl
Konstantinos Chiotis
@sl
prefLabel
Konstantinos Chiotis
@ast
Konstantinos Chiotis
@en
Konstantinos Chiotis
@es
Konstantinos Chiotis
@nl
Konstantinos Chiotis
@sl
P106
P31
P496
0000-0002-5679-0297